Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res (2010) 1.62

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat (2013) 1.34

Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer (2011) 1.19

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol (2008) 1.17

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches. Br J Cancer (2011) 1.08

Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. J Korean Med Sci (2009) 0.90

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC Cancer (2013) 0.90

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification. Breast Cancer Res (2007) 0.89

Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Exp Ther Med (2014) 0.83

[ErbB2 diagnostics in breast cancer--an update]. Pathologe (2009) 0.82

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat (2016) 0.79

Evaluation of chromosome 17 polysomy in breast cancer by FISH analysis of whole nuclei, and its clinicopathological significance. Oncol Lett (2014) 0.77

Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer (2016) 0.75

Signatures of mutational processes in human cancer. Nature (2013) 21.63

International network of cancer genome projects. Nature (2010) 20.35

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74

The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res (2008) 6.63

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11

Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res (2008) 5.88

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol (2013) 5.67

Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27

Evaluation of the Infinium Methylation 450K technology. Epigenomics (2011) 4.90

hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86

Adductor canal block versus femoral nerve block for total knee arthroplasty: a prospective, randomized, controlled trial. Anesthesiology (2014) 3.80

Perioperative outcomes after unilateral and bilateral total knee arthroplasty. Anesthesiology (2009) 3.66

Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst (2002) 3.40

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics (2008) 3.24

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol (2008) 3.23

Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol (2007) 2.90

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol (2006) 2.84

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol (2008) 2.66

Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (2012) 2.64

Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med (2010) 2.62

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol (2012) 2.50

A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst (2012) 2.34

Structural basis for assembly and function of a heterodimeric plant immune receptor. Science (2014) 2.34

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol (2013) 2.26

Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res (2009) 2.19

CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18

A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res (2008) 2.16

Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res (2004) 2.12

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11

Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. Int Urol Nephrol (2013) 2.07

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst (2008) 1.95

Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol (2009) 1.93

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90

What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol (2004) 1.89

Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res (2005) 1.86

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat (2009) 1.86

A cross-sectional survey on prevalence and risk factors for persistent postsurgical pain 1 year after total hip and knee replacement. Reg Anesth Pain Med (2012) 1.86

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85

18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med (2013) 1.82

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev (2013) 1.82

DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med (2011) 1.81

Perioperative pulmonary outcomes in patients with sleep apnea after noncardiac surgery. Anesth Analg (2010) 1.80

Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer. J Virol (2008) 1.79

Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res (2012) 1.77

HER2-positive circulating tumor cells in breast cancer. PLoS One (2011) 1.73

Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One (2011) 1.72

Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics (2008) 1.71